Understanding the differences between

Mixed Amphetamine Salts
(MAS) Formulations

Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The exact mode of therapeutic action in Attention Deficit Hyperactivity Disorder (ADHD) is not known. Amphetamines block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space.1

The first amphetamine product (mixed amphetamine salts, or MAS, immediate-release) was approved for the treatment of ADHD in 1996. MAS have been used for the treatment of ADHD for over 20 years.2

3 TYPES OF MAS FORMULATIONS

MAS formulations differ in dosage, mechanism of release, pharmacokinetics, and duration of effect.
Three common formulations are presented below.1-4

MAS formulations differ in dosages, mechanism of release, pharmacokinetics, and duration of effect.

Tablet and capsules shown are not actual size.

*Definitive clinical trials comparing MAS IR, MAS ER (other), and Mydayis have not been performed. Duration of effect is not described in MAS IR and MAS ER (other) labels; estimates are from Jain and Katic, 2016.4
No estimates of onset for MAS IR and MAS ER (other) were provided in this publication.

Dosing

To avoid substitution errors and overdosage, do not substitute for other amphetamine products on a milligram-per-milligram basis because of different amphetamine base compositions and differing pharmacokinetic profiles.

To avoid substitution errors and overdosage, do not substitute for other amphetamine products on a milligram-per-milligram basis  because of different amphetamine base compositions and differing PK profiles.

Tablet and capsules shown are not actual size.

References
  1. Mydayis [package insert]. Lexington, MA; Shire US Inc.
  2. Adderall XR [package insert]. Wayne, PA: Shire US Inc.
  3. Spencer TJ, Adler LA, Weisler RH, Youcha SH. Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study. J Clin Psychiatry. 2008;69(9):1437-1448.
  4. Jain R, Katic A. Current and investigational medication delivery systems for treating attention-deficit/hyperactivity disorder. Prim Care Companion CNS Disord. 2016;18(4):doi:10.4088/PCC.16r01979.